By Stephen Nakrosis 
 

Cara Therapeutics and Vifor Pharma on Monday said the U.S. Food and Drug Administration approved the Korsuva injection to treat pruritus in hemodialysis patients.

The companies said the Korsuva, or difelikefalin, injection was approved to treat moderate-to-severe pruritus in hemodialysis patients.

The companies said the Korsuva injection is the first and only therapy approved by the FDA to treat pruritus associated with chronic kidney disease in adult patients undergoing hemodialysis.

The companies said the promotional launch of Korsuva injection in the U.S. is expected in the first quarter of next year.

 

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

 

(END) Dow Jones Newswires

August 23, 2021 16:46 ET (20:46 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Cara Therapeutics Charts.
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Cara Therapeutics Charts.